Aflibercept

EYDENZELT, EYLEA, EYLEA HD

Vascular Endothelial Growth Factor Inhibitor

NADAC/unit N/A

No Shortage

Aflibercept blocks blood vessel growth to treat cancer or retinal diseases.

Covered Lives

Market Intelligence

2024-06-05 Class II Recall: Regeneron Pharmaceuticals Inc

2024-05-08 Class II Recall: Regeneron Pharmaceuticals Inc

Explore in the Ecosystem

rxsaver.aiCompare prices for Aflibercept drfinder.aiFind doctors who prescribe Aflibercept rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Aflibercept

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.